Enteral nutrition to suppress postoperative Crohn's disease recurrence: a five-year prospective cohort study

Int J Colorectal Dis. 2013 Mar;28(3):335-40. doi: 10.1007/s00384-012-1587-3. Epub 2012 Sep 27.

Abstract

Purpose: The aim of this study was to investigate the long-term effect of enteral nutrition (EN) as a maintenance therapy in Crohn's disease (CD) patients following surgery.

Methods: This study was an extension of our previous study to prolong the duration of intervention and follow-up from 1 to 5 years. Forty consecutive patients who underwent resection for ileal or ileocolic CD were included. Following surgery, 20 patients received continuous elemental diet infusion during the nighttime plus a low-fat diet during the daytime (EN group). Another 20 patients received neither nutritional therapy nor food restriction (control group). All patients were followed for 5 years after operation. No patient received corticosteroid, immunosuppressants, or infliximab except patients who developed recurrence. The end point of this study was recurrence requiring biologic therapy or reoperation. Recurrence rates were analyzed on an intention-to-treat basis.

Results: In the EN group, four patients could not continue tube intubation for elemental diet intake. Two patients (10 %) in the EN group and nine patients (45 %) in the control group developed recurrence requiring infliximab therapy (P = 0.03). The cumulative recurrence incidence rate requiring infliximab was significantly lower in the EN group vs the control group (P = 0.02). One patient (5 %) in the EN group and five patients (25 %) in the control group required reoperation for recurrence (P = 0.18). The cumulative incidence of reoperation was lower in the EN group vs the control group, the difference not being significant (P = 0.08).

Conclusion: The outcomes of this study suggest that EN therapy reduces the incidence of postoperative CD recurrence.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Biological Therapy
  • Crohn Disease / drug therapy
  • Crohn Disease / prevention & control*
  • Crohn Disease / surgery*
  • Endoscopy
  • Enteral Nutrition* / adverse effects
  • Female
  • Humans
  • Inflammation
  • Infliximab
  • Male
  • Patient Compliance
  • Prospective Studies
  • Recurrence
  • Reoperation

Substances

  • Antibodies, Monoclonal
  • Infliximab